RecruitingPhase 4

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

United States48 participantsStarted 2025-01-08

Plain-language summary

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI.
✓. Age between 18 and 75 years old
✓. Able to provide written informed consent

Exclusion criteria

✕. Prior history of stent thrombosis
✕. PCI within 90 days.
✕. History of stroke/TIA
✕. Age \> 75 years old
✕. Weight \< 60 kg
✕. History of intracranial hemorrhage
✕. On treatment with any oral anticoagulant or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
✕. Patients with known coagulation disorders

What they're measuring

Platelet reactivity measured by VerifyNow

Timeframe: 21±7 days

Trial details

NCT IDNCT06691191

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-31

Contact for this trial

Francesco Franchi, MD

9042445515 francesco.franchi@jax.ufl.edu

View on ClinicalTrials.gov More Coronary Artery Disease trials